We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
-0.50 | -1.13% | 43.71 | 44.42 | 43.333 | 44.38 | 15,957,596 | 22:11:50 |
By Colin Kellaher
Bristol Myers Squibb Co. on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of the combination of its Opdivo and Yervoy cancer drugs for the first-line treatment of adults with unresectable malignant pleural mesothelioma.
The New York biopharmaceutical company said the recommendation is based on positive results from a Phase 3 study in which the combination showed significantly superior overall survival compared with standard-of-care chemotherapy.
The European Commission, which generally follows CHMP's advice, will now review the recommendation.
Bristol Myers said the combination, if approved, would be the first new treatment option in Europe in 15 years that has shown improved survival in malignant pleural mesothelioma, a cancer of the lining of the lungs that is frequently caused by inhaling asbestos fibers.
Opdivo plus Yervoy-based combinations are already approved in the EU for indications in non-small cell lung cancer, melanoma and renal cell carcinoma.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
April 23, 2021 07:22 ET (11:22 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions